Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland.
Geneva Centre for Inflammation Research, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
J Infect Dis. 2023 Aug 4;228(Suppl 1):S13-S23. doi: 10.1093/infdis/jiad148.
Immune-mediated inflammatory diseases (IMIDs) are a highly heterogeneous group of diseases that share a common etiology of immune dysregulation, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, among others. It is estimated that the prevalence of IMIDs ranges between 5% and 7% in developed countries. As current management of IMIDs includes the use of immunomodulatory medications, the resulting weakened immune response can increase the risk of infection, including with SARS-CoV-2 (the causative agent of COVID-19) and reduce response to vaccination, placing these individuals at continued risk of severe outcomes from COVID-19. In this article, we summarize the current literature related to COVID-19 outcomes and the immunogenicity and reactogenicity of COVID-19 mRNA vaccination among patients with rheumatologically dominated IMIDs, as well as the effect of immunomodulatory therapies on these outcomes. We conclude by providing current COVID-19 vaccination recommendations for individuals with IMID.
免疫介导的炎症性疾病（IMIDs）是一组高度异质性的疾病，它们具有免疫失调的共同病因，如类风湿关节炎、炎症性肠病和银屑病等。据估计，在发达国家，IMIDs 的患病率在 5%至 7%之间。由于目前对 IMIDs 的治疗包括使用免疫调节药物，由此导致的免疫反应减弱会增加感染的风险，包括感染 SARS-CoV-2（COVID-19 的病原体）和降低疫苗接种的反应，使这些人持续面临 COVID-19 严重后果的风险。在本文中，我们总结了目前关于风湿性主导的 IMIDs 患者 COVID-19 结局以及 COVID-19 mRNA 疫苗接种的免疫原性和反应原性的文献，以及免疫调节治疗对这些结局的影响。最后，我们为 IMID 患者提供了当前 COVID-19 疫苗接种建议。
